Astragalus
polysaccharides (APS), the main effective component of Astragalus membranaceus, can inhibit
tumor growth, but the underlying mechanisms remain unclear. Previous studies have suggested that APS can regulate the gut microenvironment, including the gut microbiota and fecal metabolites. In this work, our results showed that APS could control
tumor growth in
melanoma-bearing mice. It could reduce the number of myeloid-derived suppressor cells (MDSC), as well as the expression of MDSC-related molecule Arg-1 and
cytokines IL-10 and TGF-β, so that CD8+ T cells could kill
tumor cells more effectively. However, while APS were administered with an
antibiotic cocktail (ABX), MDSC could not be reduced, and the growth rate of
tumors was accelerated. Consistent with the changes in MDSC, the serum levels of
IL-6 and IL-1β were lowest in the APS group. Meanwhile, we found that fecal
suspension from mice in the APS group could also reduce the number of MDSC in
tumor tissues. These results revealed that APS regulated the immune function in
tumor-bearing mice through remodeling the gut microbiota. Next, we focused on the results of
16S rRNA, which showed that APS significantly regulated most microorganisms, such as Bifidobacterium pseudolongum, Lactobacillus johnsonii and Lactobacillus. According to the Spearman analysis, the changes in abundance of these microorganisms were related to the increase of metabolites like
glutamate and
creatine, which could control
tumor growth. The present study demonstrates that APS attenuate the immunosuppressive activity of MDSC in
melanoma-bearing mice by remodeling the gut microbiota and fecal metabolites. Our findings reveal the therapeutic potential of APS to control
tumor growth.